News

Apnimed Announces First Patient Dosed in a Second Phase 2 Clinical Trial with AD109, a Disease Modifying Candidate for Obstructive Sleep Apnea

Apnimed, a clinical-stagepharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating AD109 as a treatment for mild to moderate OSA. If successful, AD109 could offer an entirely new approach to treating OSA with a once-daily, oral medication that addresses the underlying biology of the disease.

Apnimed to Present at World Sleep Virtual Conference

CAMBRIDGE, Mass. November 30, 2020 – Apnimed, a clinical-stage pharmaceutical company focused on advancing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that Dr. Luigi Taranto Montemurro, the company’s Medical Director will present at the World Sleep Conference, held virtually December 3-5, 2020. Dr. Taranto Montemurro’s presentation discussing pharmacotherapy for OSA is scheduled for Friday, December 4th from 6:00 – 6:30 PM EST.

Apnimed to Participate in Fireside Chat at the Evercore ISI HealthCONx Conference

CAMBRIDGE, Mass. November 30, 2020 – Apnimed, a clinical-stage pharmaceutical company focused on advancing medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that Larry Miller, M.D., Chief Executive Officer, will participate in a fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference, held virtually December 1-3, 2020. The presentation is scheduled for Thursday, December 3rd from 1:50 PM – 2:10 PM ET.

Apnimed Announces First Patient Dosed in Phase 2 Clinical Trial with AD109, Lead Candidate for Treatment of Obstructive Sleep Apnea

CAMBRIDGE, Mass. November 24, 2020 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that the first patient has been dosed in first Phase 2 clinical trial evaluating AD109, the company’s first-in-class, oral pharmaceutical under development for the treatment of OSA. If successful, this pharmacologic approach could substantially change the treatment paradigm for OSA patients.

Apnimed Further Strengthens Leadership Team and Board of Directors

CAMBRIDGE, Mass. November 10, 2020 – Apnimed, a clinical-stage pharmaceutical company focused on developing medicines to treat sleep apnea and related disorders, today announced it has added two highly experienced executives to help lead the company. Michael Rogers joins Apnimed as Chief Financial Officer and brings more than 25 years of biotechnology experience in both private and public finance management. Additionally, Jay Galeota joins the company’s Board of Directors, and brings more than 30 years of commercial, operational, and company building experience in large pharmaceutical, specialty generics, and biotechnology companies to Apnimed’s Board of Directors.

Apnimed Successfully Completes Phase 1 Study in Lead Program for Obstructive Sleep Apnea

CAMBRIDGE, Mass. September 17, 2020 – (BUSINESSWIRE) – Apnimed, a clinical-stage pharmaceutical company focused on developing medicines to treat sleep apnea and related disorders, today announced the results of a Phase 1 study for a component of the company’s lead combination drug candidate, AD109, which is being explored as a pharmacologic treatment for Obstructive Sleep Apnea (OSA). In this healthy volunteer study, R-oxybutynin, a key component of AD109, demonstrated a favorable pharmacokinetic (PK) profile and was well tolerated with no adverse events related to the study drug.

Apnimed Strengthens its Scientific Advisory Board with Experts in Sleep Disorders

CAMBRIDGE, Mass. September 17, 2020 – Apnimed, a clinical-stage pharmaceutical company focused on advancing medicines to treat sleep apnea and related disorders, today announced its Scientific Advisory Board (SAB). The SAB will help guide the advancement of the company’s pipeline of small molecule solutions for the treatment of Obstructive Sleep Apnea, or OSA.

Apnimed to Present at Oppenheimer’s Private Life Sciences Company Call Series

Cambridge, Mass. August 12, 2020 – Apnimed, a clinical-stage pharmaceutical company focused on advancing medicines to treat sleep apnea and related disorders, today announced that the company will present at Oppenheimer’s Private Life Sciences Company Call Series, held virtually August 17-19, 2020. The company’s presentation is scheduled for Monday, August 17th from 9:15 AM – 9:50 AM ET.

Luigi Taranto Montemurro, M.D., Joins Apnimed as Company Develops Groundbreaking Pharmacologic Therapeutics for Obstructive Sleep Apnea

Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for sleep apnea and related disorders, today announced that Luigi Taranto Montemurro, M.D., a co-founder of the company, has joined the team full-time as Medical Director. Dr. Taranto Montemurro brings extensive clinical experience in treating patients with Obstructive Sleep Apnea (OSA) and has conducted seminal research responsible for the formation of the company. He is a recognized expert in the evaluation of pharmacotherapeutics for OSA and in the development of precision therapies targeted at OSA phenotypes.

Sign up for email updates.

Select list(s) to subscribe to


By submitting this form, you are consenting to receive marketing emails from: Apnimed, 20 Holyoke Street, Cambridge, MA, 02138, http://www.apnimed.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

View our Privacy Policy